{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:28:30Z","timestamp":1792290510190,"version":"4.4.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.hoc.2016.11.008","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T16:52:10Z","timestamp":1490287930000},"page":"297-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Mycosis Fungoides and Sezary Syndrome"],"prefix":"10.1016","volume":"31","author":[{"given":"Francine M.","family":"Foss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2016.11.008_bib1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clml.2012.06.010","article-title":"Age, race, sex, stage, and incidence of cutaneous lymphoma","volume":"12","author":"Wilson","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2016.11.008_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000106410","article-title":"Environmental risk factors for mycosis fungoides","volume":"35","author":"Wohl","year":"2007","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib5","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","article-title":"Infections complicating mycosis fungoides and Sezary syndrome","volume":"267","author":"Axelrod","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2016.11.008_bib6","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood-2003-04-1044","article-title":"Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma","volume":"102","author":"Yawalkar","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/gcc.10184","article-title":"Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma","volume":"37","author":"Mao","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.hoc.2016.11.008_bib8","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood.V95.9.2937.009k15_2937_2942","article-title":"Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN","volume":"95","author":"Scarisbrick","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/138920212799034767","article-title":"Interference between DNA replication and transcription as a cause of genomic instability","volume":"13","author":"Lin","year":"2012","journal-title":"Curr Genomics"},{"key":"10.1016\/j.hoc.2016.11.008_bib10","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1158\/0008-5472.CAN-04-0366","article-title":"Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue","volume":"65","author":"Karenko","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2016.11.008_bib11","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T\u00a0cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2016.11.008_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib13","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","article-title":"Defining early mycosis fungoides","volume":"53","author":"Pimpinelli","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/1523-1747.ep12389114","article-title":"Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides\/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR\/DGGE)","volume":"103","author":"Wood","year":"1994","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2010.08.037","article-title":"Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)","volume":"64","author":"Olsen","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-4362.1988.tb03219.x","article-title":"Sezary cell count in exfoliative dermatitis","volume":"27","author":"Duangurai","year":"1988","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib17","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaad.2015.12.018","article-title":"Cutaneous T-cell lymphoma (CTCL): current practices in blood assessment and the utility of T-cell receptor (TCR)-Vbeta chain restriction","volume":"74","author":"Gibson","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib18","first-page":"725","article-title":"Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.hoc.2016.11.008_bib19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0046-8177(85)80177-5","article-title":"Histologic assessment of lymph nodes in mycosis fungoides\/Sezary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system","volume":"16","author":"Sausville","year":"1985","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hoc.2016.11.008_bib20","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/blood.V79.12.3293.3293","article-title":"Prognostic implications of evaluation for lymph node involvement by T-cell antigen receptor gene rearrangement in mycosis fungoides","volume":"79","author":"Lynch","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/1097-0142(19930801)72:3<726::AID-CNCR2820720316>3.0.CO;2-P","article-title":"Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sezary syndrome","volume":"72","author":"Graham","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.11.008_bib22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-109-5-372","article-title":"Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups","volume":"109","author":"Sausville","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2016.11.008_bib24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/ajcp\/92.6.747","article-title":"Marrow involvement in cutaneous T-cell lymphoma. A clinicopathologic study of 60 cases","volume":"92","author":"Salhany","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hoc.2016.11.008_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0190-9622(97)70212-3","article-title":"Prognostic factors and evaluation of mycosis fungoides and Sezary syndrome","volume":"37","author":"Toro","year":"1997","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib27","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archderm.1995.01690210033005","article-title":"Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome","volume":"131","author":"Kim","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1987.5.2.208","article-title":"Cytologic transformation in cutaneous T\u00a0cell lymphoma: a clinicopathologic entity associated with poor prognosis","volume":"5","author":"Dmitrovsky","year":"1987","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib30","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib31","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.138.1.42","article-title":"Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT)","volume":"138","author":"Stevens","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2133.2006.07367.x","article-title":"18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma","volume":"155","author":"Kumar","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archderm.142.5.577","article-title":"Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography","volume":"142","author":"Tsai","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/0360-3016(95)00214-8","article-title":"Radiation-induced apoptosis: relevance to radiotherapy","volume":"33","author":"Dewey","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1467","key":"10.1016\/j.hoc.2016.11.008_bib36","first-page":"e66","article-title":"In brief: mechlorethamine gel (Valchlor) for cutaneous T-cell lymphoma","volume":"57","year":"2015","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.hoc.2016.11.008_bib37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/17512433.2014.944500","article-title":"Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma","volume":"7","author":"Talpur","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.hoc.2016.11.008_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0781.2007.00314.x","article-title":"Narrow-band ultraviolet therapy in early-stage mycosis fungoides: study on 20 patients","volume":"23","author":"Brazzelli","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.hoc.2016.11.008_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib41","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mjd.2002.123482","article-title":"Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group","volume":"47","author":"Jones","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib43","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/j.ijrobp.2011.01.023","article-title":"Revisiting low-dose total skin electron beam therapy in mycosis fungoides","volume":"81","author":"Harrison","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2016.11.008_bib44","first-page":"1985","article-title":"Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome)","volume":"85","author":"Jones","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.11.008_bib45","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0889-8588(03)00108-4","article-title":"Total skin electron beam radiotherapy for patients who have mycosis fungoides","volume":"17","author":"Jones","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.hoc.2016.11.008_bib46","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/archderm.1995.01690160060009","article-title":"Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation","volume":"131","author":"Licata","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib47","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0360-3016(94)00590-H","article-title":"Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides","volume":"32","author":"Becker","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2016.11.008_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0190-9622(96)90499-5","article-title":"Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma","volume":"35","author":"Wilson","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib49","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0360-3016(98)00517-3","article-title":"Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides","volume":"43","author":"Chinn","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2016.11.008_bib50","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0360-3016(97)00127-2","article-title":"Total skin electron beam therapy followed by adjuvant psoralen\/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)","volume":"38","author":"Quiros","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2016.11.008_bib51","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0360-3016(95)00073-8","article-title":"Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy","volume":"32","author":"Wilson","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2016.11.008_bib52","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.hoc.2016.11.008_bib53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jdermsci.2005.01.005","article-title":"Treatment with IFN-gamma increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides","volume":"38","author":"Hino","year":"2005","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.hoc.2016.11.008_bib54","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/82.3.208","article-title":"Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kaplan","year":"1990","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2016.11.008_bib55","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2006.06.038","article-title":"A\u00a0phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides","volume":"55","author":"Duvic","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib56","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2006.08.067","article-title":"Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sezary syndrome","volume":"56","author":"Querfeld","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib57","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2009-11-256040","article-title":"Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy","volume":"116","author":"Berger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/153303460200100109","article-title":"Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization","volume":"1","author":"Girardi","year":"2002","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.hoc.2016.11.008_bib59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/12034754030070S402","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2003","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.hoc.2016.11.008_bib60","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0781.2012.00689.x","article-title":"Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2012","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.hoc.2016.11.008_bib61","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1067\/mjd.2000.104852","article-title":"Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution","volume":"43","author":"Bisaccia","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib62","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","article-title":"Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib63","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.det.2015.05.007","article-title":"The role of systemic retinoids in the treatment of cutaneous T-cell lymphoma","volume":"33","author":"Huen","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.hoc.2016.11.008_bib64","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.20952","article-title":"Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine","volume":"82","author":"Richardson","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2016.11.008_bib65","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib66","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib67","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.11.008_bib68","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib69","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib70","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib71","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib72","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib73","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2016.11.008_bib74","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib75","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1158\/0008-5472.CAN-07-1148","article-title":"A\u00a0human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity","volume":"67","author":"Rider","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2016.11.008_bib76","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2016.11.008_bib77","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib78","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib79","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"CD30 expression and proliferative fraction in nontransformed mycosis fungoides","volume":"33","author":"Edinger","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hoc.2016.11.008_bib80","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab Vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib81","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib82","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.11.008_bib83","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib84","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/archderm.135.10.1279","article-title":"Low-dose 2-chlorodeoxyadenosine for the treatment of mycosis fungoides","volume":"135","author":"Trautinger","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib85","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","article-title":"Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study","volume":"82","author":"Von Hoff","year":"1990","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2016.11.008_bib86","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib87","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.11.008_bib88","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2016.11.008_bib89","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib90","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.hoc.2016.11.008_bib91","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00280-009-0954-4","article-title":"Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in\u00a0vitro and in\u00a0vivo models of human cancers","volume":"64","author":"Izbicka","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2016.11.008_bib92","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib93","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2016.11.008_bib94","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","article-title":"Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome","volume":"123","author":"Querfeld","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.11.008_bib95","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides","volume":"23","author":"Molina","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.11.008_bib96","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/bmt.2011.201","article-title":"Allogeneic hematopoietic SCT for primary cutaneous T\u00a0cell lymphomas","volume":"47","author":"Paralkar","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2016.11.008_bib97","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2016.11.008_bib98","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:04:39Z","timestamp":1760184279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816301769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0889858816301769"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycosis Fungoides and Sezary Syndrome","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}